The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy by Ericsson, A et al.
ORIGINAL RESEARCH
The effects of dual PPARa/c agonism compared with ACE
inhibition in the BTBRob/ob mouse model of diabetes and
diabetic nephropathy
Anette Ericsson1, Pernilla Tonelius1, Mark Lal1, Alan Sabirsh1, Gerhard B€ottcher2,
Lena William-Olsson1, Maria Str€omstedt1, Camilla Johansson2, Gina Hyberg2, Sofia Tapani3,
Ann-Cathrine J€onsson-Rylander1 & Robert Unwin1
1 Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D Gothenburg, M€olndal, Sweden
2 Drug, Safety & Metabolism, AstraZeneca R&D Gothenburg, M€olndal, Sweden
3 Discovery Sciences Innovative Medicines Research Unit, AstraZeneca R&D Gothenburg, M€olndal, Sweden
Keywords
angiotensin-converting enzyme, BTBRob/ob
mouse, diabetic kidney disease, peroxisome
proliferator-activated receptor.
Correspondence
Anette Ericsson, Department of CKD,
Cardiovascular & Metabolic Disease
Innovative Medicines, AstraZeneca R&D
Gothenburg, Pepparedsleden 1, 431 83
M€olndal, Sweden.
Tel: +46-31-7761000
E-mail: anette.e.ericsson@astrazeneca.com
Funding Information
All studies were funded by AstraZeneca.
Received: 20 December 2016; Revised: 31
January 2017; Accepted: 5 February 2017
doi: 10.14814/phy2.13186
Physiol Rep, 5 (5), 2017, e13186,
doi: 10.14814/phy2.13186
Abstract
The leptin-deficient BTBRob/ob mouse develops progressive albuminuria and
morphological lesions similar to human diabetic nephropathy (DN), although
whether glomerular hyperfiltration, a recognized feature of early DN that may
contribute to renal injury, also occurs in this model is not known. Leptin
replacement has been shown to reverse the signs of renal injury in this model,
but in contrast, the expected renoprotection by angiotensin-converting
enzyme (ACE) inhibition in BTBRob/ob mice seems to be limited. Therefore,
to investigate the potential renal benefits of improved metabolic control in
this model, we studied the effect of treatment with the dual peroxisome pro-
liferator-activated receptor (PPAR) a/c agonist AZD6610 and compared it
with the ACE inhibitor enalapril. AZD6610 lowered plasma glucose and
triglyceride concentrations and increased liver size, but had no significant
effect in reducing albuminuria, whereas enalapril did have an effect. Nephrin
and WT1 mRNA expression decreased in the kidneys of BTBRob/ob mice,
consistent with podocyte injury and loss, but was unaffected by either drug
treatment: at the protein level, both nephrin and WT1-positive cells per
glomerulus were decreased. Mesangial matrix expansion was reduced in
AZD6610-treated mice. GFR, measured by creatinine clearance, was increased
in BTBRob/ob mice, but unaffected by either treatment. Unexpectedly, enala-
pril-treated mice showed intrarenal arteriolar vascular remodeling with con-
centric thickening of vessel walls. In summary, we found that the BTBRob/ob
mouse model shows some similarities to the early changes seen in human
DN, but that ACE inhibition or PPARa/c agonism afforded limited or no kid-
ney protection.
Introduction
The global “epidemic” of type 2 diabetes will lead to an
increase in the number of patients developing chronic
kidney disease (CKD) and end-stage renal disease (ESRD)
eventually requiring dialysis and renal transplantation.
The typical early renal structural lesions seen in diabetes
include thickening of the glomerular basement membrane
(GBM) and mesangial expansion, with later more
advanced glomerular scarring and classical Kimmelstiel–
Wilson nodule formation; podocytes, the tubulointersti-
tium, and arterioles are also affected with podocyte loss,
interstitial fibrosis, and arteriolar hyalinosis (Fioretto and
Mauer 2007).
To improve our understanding of the pathogenesis of
diabetic nephropathy (DN), and to identify potential
therapeutic targets, better animal models of human DN
are still needed. The BTBRob/ob mouse is one model that
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has been reported to mimic reliably many of the typical
early pathological features of human DN. These mice
have been shown to develop progressive albuminuria with
early accumulation of mesangial matrix and loss of
glomerular podocytes, and in older mice there is GBM
thickening, diffuse mesangial sclerosis, arteriolar hyali-
nosis, and mesangiolysis (Hudkins et al. 2010).
Peroxisome proliferator–activated receptors (PPARs)
play an important role in metabolic diseases associated
with hyperlipidemia and insulin resistance, and in dia-
betes mellitus. Both PPARa and -c are expressed in the
kidney (Yang et al. 1999; Guan and Breyer 2001), and
their agonists have shown renoprotective effects in type
2 diabetes. Although PPARa and -c agonists have shown
some promise as treatments for DN (Keech et al. 2005;
Sarafidis et al. 2010), their adverse side effects can
include fluid retention, increased risk of myocardial
infarction (Nesto et al. 2003), and elevated serum crea-
tinine levels (McQuade et al. 2008); although the latter
is often short-lived and reversible (Mychaleckyj et al.
2012).
The renoprotective effects of PPAR agonists have
been demonstrated in the leptin receptor-deficient and
insulin-resistant db/db mouse model of DN. Fenofibrate
(PPARa agonist) treatment in this model was shown to
reduce glucose and insulin levels, albuminuria, glomeru-
lar hypertrophy, and mesangial expansion (Park et al.
2006). In the same mouse model, rosiglitazone (PPARc
agonist) was found to lower blood glucose and triglyc-
erides levels, but was without effect on insulin levels,
and failed to decrease albuminuria and mesangial
expansion (Chodavarapu et al. 2013). The dual PPARa/
c agonist, tesaglitazar, has also been shown to decrease
blood glucose, insulin, and triglyceride concentrations,
as well as albuminuria and glomerular lesions (Cha
et al. 2007).
In a recent study using the PPARa agonist CP-900691
in the BTBRob/ob mouse model, Askari et al. (2014)
reported that while treatment improved glucose and
triglyceride levels, it did not affect insulin levels, albumin-
uria, or mesangial expansion. In contrast, the widely used
ACE inhibitor enalapril, commonly prescribed to patients
with DN, has been shown to reduce albuminuria in the
BTBRob/ob mouse model, but with only modest effects
on renal histology (Pichaiwong et al. 2013).
Thus, given the conflicting data discussed above and
the uncertainty over the beneficial renal effects of PPAR
agonists in different mouse models, as well as the limited
studies of renoprotection particularly in the BTBRob/ob
model of DN, we wanted to investigate the effect of a
dual PPARa/c agonist, AZD6610, and compare it with
RAS blockade using the ACE inhibitor enalapril, starting
treatment at 17 weeks of age when the mice consistently
show features of DN. Our aim was to evaluate the efficacy
of interventional treatment in mice consistently showing
features of established DN, rather than as preventive ther-
apy, starting at the onset of albuminuria (~6–8 weeks
age) with only modest morphological alterations, so as to
better reflect current treatment strategies in patients.
Materials and Methods
Ethical approval
Experimental procedures were approved (ethical applica-
tion number 109-2012) by the Regional Laboratory Ani-
mal Ethics Committee of Gothenburg, Sweden. All
procedures conform to the Swedish Animal Welfare Act
and regulations SJVFS 2012: 26.
Animals
BTBR.V(B6)-Lepob/WiscJ stock no. 004824 mice were
purchased from Jackson Laboratories (Bar Harbor, ME).
Mice were delivered to our facility at ages 4–6 weeks.
Animals were housed in communal cages (2–3 mice/cage)
equipped with heated areas. The bedding was changed
twice weekly and mice had free access to chow diet. The
mice were randomized according to body weight, fasting
glucose, and HbA1C into the following groups at 8 weeks
of age: (1) BTBRob/ob controls (n = 12); (2) BTBRob/ob
treated with enalapril (Sigma E6888-5G) dissolved in
drinking water 200 mg/l (40 mg/kg/day) with a noncalo-
ric sweetener (Splenda, 240 mg/l) from 14 weeks of age
(n = 7); (3) BTBRob/ob treated with the dual PPARa/c
agonist AZD6610 added to the diet at the glucose lower-
ing dose of 0.012 mg/g (3 lmol/kg/day) started at
17 weeks of age, which was preceded by a nonglucose
lowering dose (1 lmol/kg/day) started at 14 weeks of age
(n = 8); (4) BTBR lean control mice (n = 5). The main
aim of the study was to evaluate the efficacy of the treat-
ments in mice with established DN (at 14–17 weeks age),
rather than as a preventive therapy. Only female mice
were used in these experiments.
At the age of 24 weeks, all mice were anesthetized with
isoflurane and loss of pedal reflexes confirmed before the
mice were euthanized by exsanguination and disruption
of blood flow. Another separate group of male BTBRob/
ob (n = 5) mice that had similar blood chemistry to
females (data not shown) and a group of lean control
BTBR mice (n = 5) were used to measure glomerular fil-
tration rate (GFR) more accurately than by creatinine
clearance using FITC-sinistrin clearance. Other separate
subgroups of female BTBRob/ob (n = 6) and lean (n = 6)
mice were used to measure systolic blood pressure in con-
scious mice by the tail cuff method.
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Blood analyses
Repeated blood glucose and HbA1C levels were measured
in the 3-h fasted awake mouse using Accu-Chek (Roche,
REF 05599415370) and HbA1C Now+ (Bayer, REF
81611409-3038), respectively. Creatinine was analyzed on
a LC-MS/MS system consisting of a Waters Quattro
Premiere mass spectrometer and an Agilent 1100 HPLC.
Column was a Phenomenex Kinetex HILIC 2.6 l,
2.1 9 100 mm. Mobile phase A was acetonitrile and
mobile phase B was 40 mmol/L ammonium formate.
Gradient was from 5% B to 50% B in 10 min with 5 min
equilibration time. As internal standard, 0.2 lmol/L D3-
creatinine in ACN:H2O, 9:1 was used. On termination at
24 weeks of age, blood samples were collected and sepa-
rated plasma were analyzed for insulin and adiponectin
using radioimmunoassays (Cat No. RI-13K and MADP-
60HK, Merck Millipore, Darmstadt, Germany) and
triglycerides using an enzymatic colorimetric method (Kit
No. 12146029 triglycerides/GB, Roche Diagnostics GmbH,
Mannheim, Germany).
Urine analyses
To determine albumin excretion rates (AER), 13-h urine
collections were obtained from mice housed in metabolic
cages. Urine albumin concentration was measured using a
mouse-specific albumin ELISA (E-90AL, ICL). Urine crea-
tinine was measured by the Jaffe method (Creatinine FS,
REF117119910021, DiaSys). Estimated glomerular filtra-
tion rate as measured by creatinine clearance (CCr, mL/
min) was calculated as: (Urine Cre 9 Urine volume
[mL])/(Plasma Cre 9 Time [min]).
GFR by FITC-sinistrin clearance
To assess GFR in the BTBRob/ob mouse model, we used
the two-compartment model of two-phase exponential
decay as described previously for FITC-inulin in con-
scious mice (Qi et al. 2004). However, in this experiment,
we used a single bolus injection of 0.1 mL of 15 mg/mL
FITC-sinistrin (Mannheim Pharma & Diagnostics GmbH,
Mannheim, Germany) that was given intravenously to
male BTBRob/ob and lean control mice. Repeated tail
vein blood sampling was carried out at 3, 7, 10, 15, 35,
55, and 75 min postinjection. FITC-sinistrin concentra-
tion was measured using a Beckman Coulter Paradigm
Detection System (Li et al. 2012).
Histopathology
Tissue samples were fixed in buffered formaldehyde solu-
tion, dehydrated, and embedded in paraffin wax. Two lm
sections were cut and stained with hematoxylin–eosin, peri-
odic-acid–shiffs reagent (PAS), or with immunohistochem-
istry reagents as described below. Histopathological
assessment of mesangial matrix accumulation (PAS),
podocyte markers (nephrin and WT1), and arteriolar wall
thickening (a-SMA) was performed, and the sections were
scored semiquantitatively on a scale of 0 (normal) to 5
(severe).
Glomerular basal membrane (GBM) thickness was
assessed using electron microscopy (Jeol 1400 Transmis-
sion Electron Microscopy) over three glomeruli per
kidney, images (n = 10–14) taken at 12,0009 magnifica-
tion and mean basal membrane thickness (nm)
calculated.
Immunohistochemistry
Immunohistochemistry staining was carried out for the
podocyte markers nephrin and WT1 (see Table 1 for anti-
body details).
A novel method was introduced to allow automated
unbiased quantification of nephrin and WT1 staining
in multiple, adjacent, immunostained, 2-lm transverse
kidney sections that were digitized using slide scan-
ners (Zeiss Axioscan or Zeiss Mirax, Carl Zeiss AG,
Munich, Germany), fitted with a 209 air objective
yielding images with 4.545 pixels/lm. The resulting
virtual slides were imported into Visiopharm Integra-
tor System software (version 5.3, Visiopharm, Hør-
sholm, Denmark).
For analysis, the tissues from sequential sections were
aligned and then resampled at 1.138 pixels/lm using sys-
tematic random sampling of the cortical region with cov-
erage of 60%. Machine learning and Bayesian
classification (Visiopharm, Visiomorph DP module), fol-
lowed by morphological filtering, identified tissues and
stained areas. Individual glomeruli were identified using
nephrin staining and then used to generate regions of
interest on the adjacent tissue section that had been
stained for WT1 expression. For each glomerulus, the
number of WT1-positive nuclei and the fractional area of
WT1 staining were calculated.
Table 1. Primary antibody details.
Primary antibody Host species Dilution Supplier
Nephrin Guinea pig 1:1000 Acris
WT1 Rabbit 1:200 Calbiochem
a-SMA Mouse 1:100 Dako
a-SMA, a-smooth muscle actin.
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Real-time quantitative PCR
RNA was extracted from kidney cortex and reverse
transcribed into cDNA. TaqMan gene expression
assays specific for nephrin (Nphs1, Mm00497828_m1),
WT1 (Mm01337048_m1), Tnf (Mm00443258_m1), Ccl2
(Mm00441242_m1), CD68 (Mm03047340_m1), Gapdh
(Mm99999915_g1), and Hprt (Mm01324427_m1)
(Applied Biosystems, Waltham, MA) were used. Relative
quantification was obtained using the DDCt method using
Gapdh and Hprt for normalization.
Study design
The objective of the study was to investigate the efficacy
of dual PPARa/c agonist versus ACE inhibition in
BTBRob/ob mice starting treatment at the age of
14–17 weeks. An a priori power analysis of historical in-
house data of albuminuria was performed to determine
sample sizes. For a power of b = 80% at a significance
level of a = 5%, a treatment effect from baseline albumin-
uria of 45–55% is detectable with n = 5–12 in each
group. Where the upper n-number is selected for the con-
trol group due to multiple comparisons in Dunnett’s post
hoc tests.
Statistical analysis
One-way analysis of variance (ANOVA) followed by
Dunnett’s two-sided post hoc tests for multiple compar-
isons were used to analyze data on blood and weight
parameters, GBM thickness, and on mRNA expression
data. Urine data, including creatinine clearance (CCr),
albumin excretion rate (AER), and albumin creatinine
ratio (ACR) show a right skewed distribution and so
data were log-transformed prior to performing ANOVA.
Due to the small sample size, regular tests of normality
have low power and were not performed. However,
visual inspection of diagnostic plots after log transforma-
tion indicated a better fit to a log-normal distribution.
The same transformation was used for the quantitative
computer-generated histological evaluation; all data were
normalized to the geometric mean value for the lean
control group. Data were log-transformed prior to using
standard parametric tests as described above. Repeated
measures on the same subject (Figs. 1A and 4) were
analyzed with a repeated measures two-way ANOVA
and following appropriate Dunnett’s two-sided post hoc
tests for correction of multiple comparisons. If P < 0.05
or if 95% confidence intervals were not overlapping,
results were considered significantly different. Statisti-
cal analyses were performed with Graphpad 5.0 for
Windows.
Results
Characteristics of PPARa/c ligand- and
enalapril-treated BTBRob/ob mice compared
with controls
All BTBRob/ob mouse groups had higher body weight
compared with age-matched lean BTBR controls; body
weight was unaffected by either treatment (Table 2). Liver
weights of BTBRob/ob mice were twofold higher than
lean controls, reflecting obesity-induced hepatic steatosis
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Figure 1. Blood glucose levels before and after treatment with a
PPARa/c agonist or ACE inhibitor. (A) Blood glucose levels in
conscious 3-h fasted BTBRob/ob female mice (n = 12) measured at
8 and 14 weeks of age before treatment with enalapril (n = 7) or
PPARa/c agonist (AZD6610, n = 8) and after treatment at 24 weeks
age. The time point of starting the treatments are shown with
arrows (gray, enalapril; black, PPAR). Repeated measures two-way
ANOVA and Dunnett’s tests were used. (B) HbA1C measured in 3-h
fasted BTBRob/ob mice before (14 weeks, n = 8) and after PPAR
treatment (24 weeks, n = 8). Statistical analysis was done using a
paired t-test. Values are shown as means with 95% confidence
intervals. *P < 0.05 compared with untreated BTBRob/ob and
#P < 0.05, ##P < 0.01 compared with BTBR lean. $$$P < 0.001
compared to before start of PPAR treatment. Ena, enalapril.
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and increased triglyceride content, and a mean difference
of 6.1  1.8 g triglycerides/100 g liver (90% confidence
interval 2.9 to 9.3), which is a recognized feature of the
ob/ob mutation. Hepatomegaly is also a known effect of
PPARa agonism in rodents and in the present study a
further increase (71%) in liver weight in AZD6610-treated
BTBRob/ob mice was also observed. Increased kidney
weight was found in all BTBRob/ob mice without any vis-
ible effect of treatment. Furthermore, in a small subgroup
of female mice, blood pressure was not statistically differ-
ent between BTBRob/ob (93.8  2.2 mm Hg) and BTBR
lean controls (102.6  3.0 mmHg). Blood pressure was
not measured in the treatment groups.
Terminal blood samples were taken from the anes-
thetized 3-h fasted mouse for insulin and TG analyses,
whereas glucose and HbA1C was measured in blood sam-
ples from awake 3-h fasted mice (Table 2 and Fig. 1).
The BTBRob/ob mouse was hyperglycemic (confirmed by
elevated HbA1C levels) and dyslipidemic, with high
plasma triglyceride concentrations. Treatment with the
PPARa/c agonist reduced plasma lipid concentrations,
but we were unable to detect any change in insulin levels.
The glucose-lowering effect of AZD6610 occurred within
5 days of starting treatment and was readily evident from
a marked decrease in daily water intake (pretreatment
16.1 [8.7] vs. posttreatment 9.2 [4.9] mL water/day) that
was sustained throughout the study, and reduced urinary
glucose excretion confirmed by urine dipstix testing (data
not shown). Blood glucose was measured in 3-h fasted
conscious mice at different time points (Fig. 1A). The
BTBRob/ob mice had elevated blood glucose levels com-
pared with lean controls, and following 7 weeks of
PPARa/c agonist treatment (age 17–24 weeks), blood glu-
cose (Fig. 1A) and HbA1C (Fig. 1B) were reduced. There
was one mouse that did not respond to AZD6610 treat-
ment and had persistently high plasma glucose
(25.4 mmol/L) and triglyceride (1.4 mmol/L) concentra-
tions compared with the other AZD6610-treated mice
(7.4–12.5 mmol/L glucose and 0.7–1.0 mmol/L
triglycerides). At 24 weeks of age, plasma glucose and
HbA1C levels in the enalapril treatment group did reach a
statistically significant difference compared with the
BTBRob/ob control group. The hormone adiponectin was
measured in terminal plasma to assess insulin sensitivity.
Adiponectin levels were decreased in the BTBRob/ob mice
compared with lean control mice; however, because of
the large variability in the small sample size available for
assay, we could not detect any effect of either treatment.
Renal function
Creatinine clearance (estimated GFR) was analyzed at
24 weeks of age. Creatinine clearance was increased in
female BTBRob/ob mice, suggesting the presence of
glomerular hyperfiltration (Fig. 2A). This prompted us to
measure GFR by FITC-sinistrin clearance in a small sub-
set of age-matched male BTBRob/ob mice. FITC-sinistrin
clearance was increased in the BTBRob/ob mice compared
with lean healthy controls (Fig. 2B), confirming the pres-
ence of hyperfiltration in this model, which has not been
reported before. Albumin excretion rate (AER) was ana-
lyzed at 24 weeks of age using 13-h urine collections. Uri-
nary albumin excretion rate was variable, but increased
13-fold in BTBRob/ob mice compared with lean controls;
however, AZD6610 or enalapril treatment had no statisti-
cally significant effect on albumin excretion (Fig. 3). Spot
urine albumin:creatinine ratio (ACR) was also measured
before the start of treatment and on two repeated occa-
sions during treatment. Again, there was considerable
variability in spot urine ACR, but on this measurement
enalapril did reduce albuminuria (Fig. 4). Lean BTBR
controls had lower urine ACR at all time points com-
pared with BTBRob/ob controls.
Structural alterations and podocyte markers
At 24 weeks of age, there were no apparent differences in
GBM thickness in BTBRob/ob mice compared with lean
Table 2. Weights and blood chemistry at 24 weeks age in female mice.
BTBR lean BTBRob/ob BTBRob/ob + PPAR BTBRob/ob + Ena
Body weight (g) 34.5 (3.1) 71.6 (6.1)### 70.5 (10.7) 71.9 (7.6)
Liver weight (g) 1.7 (0.1) 3.8 (0.8)### 6.5 (1.5)** 3.8 (0.9)
Total kidney weight (g) 0.39 (0.02) 0.61 (0.13)### 0.63 (0.06) 0.59 (0.06)
HbA1C (%) 4.8 (0.2) 10.5 (2.4)### 7.3 (1.9)** 7.8 (2.2)*
Insulin (nmol/L) 0.3 (0.0) 2.3 (2.6) 3.4 (3.2) 6.3 (5.4)
TG (mmol/L) 0.5 (0.1) 2.2 (1.0)### 1.0 (0.2)** 1.8 (0.6)
Adiponectin (nmol/L) 672 (271) 278 (116)### 226 (95) 312 (175)
Data are presented as means and standard deviations for the groups: BTBR lean (n = 5), BTBRob/ob (n = 11–12), BTBRob/ob + PPAR (n =
7–8), and BTBRob/ob + Ena (n = 7). ###P < 0.001 versus BTBR lean and *P < 0.05, **P < 0.01 versus BTBRob/ob vehicle control using ANOVA
and Dunnett’s post hoc test. Ena, enalapril; HbA1C, glycated hemoglobin A1C; TG, triglycerides.
ª 2017 AstraZeneca R&D Gothenburg. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2017 | Vol. 5 | Iss. 5 | e13186
Page 5
A. Ericsson et al. PPARa/c and ACE Pharmacological Effects on DN
controls and no obvious treatment effects could be
detected (Fig. 5).
Mesangial matrix expansion was evident in all BTBRob/
ob kidneys compared with lean controls and was reduced
in AZD6610-treated mice using semiquantitative scoring of
PAS staining (average scores: 0.00 in lean controls; 2.58 in
BTBRob/ob; 2.00 in BTBRob/ob + PPAR; 2.71 in BTBRob/
ob + enalapril). Using semiquantitative scoring, the change
(loss) in immunopositive staining for nephrin was found to
be increased in all BTBRob/ob mice compared with lean
mice (average score: 0.00 in lean controls; 2.67 in BTBRob/
ob; 2.75 in BTBRob/ob + PPAR; 2.43 in BTBRob/
ob + enalapril). The count of WT1-positive cells per glo-
meruli was lower in all BTBRob/ob mice compared with
lean BTBR mice (average count/glomerular area: 12.10 in
lean controls; 9.50 in BTBRob/ob; 10.70 in BTBRob/
ob + PPAR; 9.62 in BTBRob/ob + enalapril). Representa-
tive images of histopathology are shown in Figure 6.
Using automated image analysis, we quantified the
ratio between the nephrin-positive and -negative tissue
areas in each individual glomerulus as an indirect mea-
sure of matrix accumulation. The data are shown as fold
change from the lean BTBR group. There was a 2.3-fold
increase in matrix accumulation in BTBRob/ob mice,
whereas AZD6610 reduced it to 1.6-fold with a minimal,
but not statistically detectable, difference in the enalapril
group (1.9-fold) compared with lean BTBR mice
(Fig. 7A). There was one outlier in the BTBRob/
ob + PPAR group (2.8-fold increase) and this was the
nonresponder described previously for its failure to show
lowered glucose or triglycerides.
Automated image analysis was then used to quantify
nephrin and WT1 staining per glomerular area with the
lean BTBR controls given the geometric mean of 1. There
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Figure 2. Glomerular filtration rate measured by creatinine
clearance or FITC-sinistrin clearance indicates hyperfiltration is
present at 24 weeks of age. Creatinine clearance (A) was measured
by use of metabolic cages for 13 h in all female mouse groups at
24 weeks age (BTBR lean, n = 5; BTBRob/ob, n = 12; BTBRob/
ob + PPAR, n = 7; BTBRob/ob + Ena, n = 7). Values are shown as
geometric means with 95% confidence intervals and one-way
ANOVA followed by Dunnett’s multiple comparisons test were used
on log-transformed data. FITC-sinistrin clearance (B) was measured
by single bolus FITC-sinistrin injection and repeated blood sampling
in a subset of age-matched male mice (BTBR lean, n = 4; BTBRob/
ob, n = 5) and data were analyzed statistically using Student’s t-
test. Values are shown as means with 95% confidence intervals.
##P < 0.01 compared with BTBR lean. Ena, enalapril.
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Figure 3. Albumin excretion rate is increased in the BTBRob/ob
mouse. Albumin excretion rate (AER) was measured by use of
metabolic cages for 13 h in all female mouse groups at 24 weeks
age (BTBR lean, n = 5; BTBRob/ob, n = 12; BTBRob/ob + PPAR,
n = 7; BTBRob/ob + Ena, n = 7). One-way ANOVA followed by
Dunnett’s multiple comparisons test were used on log-transformed
data. Values are shown as geometric means with 95% confidence
intervals. #P < 0.01 compared with BTBR lean. Ena, enalapril.
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was decreased nephrin and WT1 positivity in all BTBRob/
ob mice compared with lean BTBR mice (Fig. 7B–C). We
could not detect any treatment effects on nephrin or WT-
1 levels in the groups we studied. The changes in podo-
cyte markers in the BTBRob/ob compared with BTBR
lean mice were also confirmed by gene expression analysis
in renal cortical tissue (Fig. 8). The statistically significant
difference in nephrin mRNA expression between BTBR
lean and BTBRob/ob was reproducible when using two
different housekeeping genes with a P-value of 0.001 for
Gapdh and 0.04 for Hprt.
An unexpected finding in this study was the presence
of concentric minimal to moderate thickening of the ves-
sel walls of the juxtaglomerular arterioles in all BTBRob/
ob mice treated with enalapril. These findings were lim-
ited to the enalapril group (with one exception of a mini-
mal finding) and the cellular wall thickening observed
was positive for a-smooth muscle actin (a-SMA) staining
(average score: 0.00 in lean controls; 0.00 in BTBRob/ob;
0.13 in BTBRob/ob + PPAR; 1.86 in BTBRob/
ob + enalapril) (Fig. 6P). No a-SMA positivity was
observed in the tubulointerstitium.
Expression levels of the inflammatory markers TNFa
(Tnf), MCP-1(Ccl2), and CD68 were analyzed and we
could not detect any differences between BTBRob/ob and
BTBR lean controls or in response to the treatments used
(Fig. 8C–E). Gene expression was normalized to both
Gapdh and Hprt with the similar results (data only
shown for Gapdh).
Discussion
The BTBRob/ob mouse model is a relatively new model
of DN that is thought to better reflect many of the typical
features of human DN, including glomerular hypertrophy,
mesangial matrix expansion, mesangiolysis, GBM thicken-
ing, podocyte loss, and albuminuria. In the present study,
we were able to confirm most of these findings, including
significant albuminuria, renal hypertrophy, mesangial
matrix expansion, and reduced expression of podocyte
markers consistent with cell injury and loss. However, in
contrast to the study by Hudkins et al. (2010), we found
more variability in some of the nephropathic features
described, specifically GBM thickness, which could
explain that we were unable to detect a difference between
diabetic animals and lean controls. In addition, we
assessed GFR for the first time in this model by measur-
ing both creatinine and FITC-sinistrin clearance. We
found evidence for glomerular hyperfiltration in the
BTBRob/ob mouse model at 24 weeks of age, which is a
recognized feature of early DN, as found in most other
diabetic mouse models, and may limit its use for transla-
tional studies of late stage human disease, and the inter-
pretation (and even concern) over therapies that may also
reduce GFR. Moreover, this mouse model does not exhi-
bit hypertension (Hudkins et al. 2010). Hypertension is
almost invariably present in human type 2 diabetes with
nephropathy, and there is still a need for animal models
that more closely resemble late human DN. Interventions
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Figure 4. ACE inhibition reduces spot urine albuminuria, but PPARa/c agonism has no effect. Albuminuria measured in female mice as
albumin:creatinine ratio (ACR) in spot urine (BTBR lean, n = 5; BTBRob/ob, n = 12; BTBRob/ob + PPAR, n = 8; BTBRob/ob + Ena, n = 7). The
time points of starting the treatments are shown with arrows (gray, enalapril; black, PPAR). Repeated measures two-way ANOVA and Dunnett’s
tests were used on log-transformed data. Values are shown as geometric means with 95% confidence intervals. *P < 0.05 compared with
untreated BTBRob/ob and ####P < 0.0001 compared with BTBR lean. Ena, enalapril.
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that have become standard clinical practice in treating
DN, and which have been shown to help slow progres-
sion, are antihypertensives, especially inhibitors of the
renin–angiotensin–aldosterone system, and tighter glyce-
mic control (Van Buren and Toto 2013). Yet despite these
mainstays of current treatment, the number of patients
progressing to end-stage renal disease remains high.
Leptin replacement in the BTBRob/ob mouse has been
shown to reverse renal injury (Pichaiwong et al. 2013),
but whether the beneficial effect of leptin is a result of
improved metabolic control or of leptin signaling itself as
a key determinant in the pathogenesis of diabetic
nephropathy is unknown. It is known that glucose lower-
ing per se may not improve renal function (Gangadharan
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Figure 5. Glomerular basement membrane (GBM) thickness was unaltered at 24 weeks of age in the BTBRob/ob mouse. Glomerular basement
membrane (GBM) thickness as measured by electron microscopy (EM) in five mice per group (females). One-way ANOVA followed by Dunnett’s
multiple comparisons test were used and values are shown as means with 95% confidence intervals. A representative EM image of a capillary
loop is shown for each treatment group. The scale bar in each image measures 3 lm. (A) BTBR lean; (B) BTBRob/ob; (C) BTBRob/ob with
PPARa/c agonist treatment; (D) BTBRob/ob with enalapril treatment. Ena, enalapril.
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Komala et al. 2014), at least in the short term. Other
studies have shown that SGLT2 inhibition, which causes
glycosuria and a lowered blood glucose concentration,
can reduce renal inflammation, albuminuria, and mesan-
gial expansion (Gembardt et al. 2014). PPAR agonists
correct several metabolic derangements in diabetes, but
also have anti-inflammatory and antiatherogenic effects,
as well as an action to lower blood pressure. Their poten-
tial renoprotective effects have been demonstrated in sev-
eral studies of nondiabetic and diabetic kidney disease,
with antifibrotic and podocyte protective effects described
previously (Guan and Breyer 2001; Zuo et al. 2012).
In the current study, a slight reduction in PAS positiv-
ity was observed following AZD6610 treatment compared
with BTBRob/ob controls, which was confirmed by both
standard histopathological semiquantitative scoring and
automated image analysis using nephrin-negative staining
as an indirect measure of glomerular matrix accumula-
tion. These findings are consistent with previous studies
(Park et al. 2006; Cha et al. 2007; Chodavarapu et al.
2013) of PPAR agonism in mouse models of type 2 dia-
betes. The novel and unbiased image analysis method
used confirms the increase in PAS positivity in the
BTBRob/ob mouse compared with lean controls, as well
as the decrease following AZD6610 treatment. However,
in contrast to the present findings, a recent study of the
PPARa agonist CP-900691 in BTBRob/ob mice showed
no effect on mesangial expansion (Askari et al. 2014).
This discrepancy could be due to the use of a PPARa ver-
sus a dual PPARa/c agonist (as in the present study),
and/or early treatment as prevention, rather than later
intervention, as well as duration of treatment.
A B C D
E F G H
I J K L
M N O P
Figure 6. Mesangial matrix in BTBRob/ob was reduced by PPARa/c agonist treatment and ACE inhibition caused thickening of arteriolar vessel
walls. Representative sections of female BTBR lean controls (A–D), BTBRob/ob (E–H), BTBRob/ob with PPARa/c agonist treatment (I–L), and
BTBRob/ob with enalapril treatment (M–P). Sections were stained with PAS (A, E, I, and M), showing mesangial matrix expansion (arrow, E) and
for podocyte markers nephrin (B, F, J and N; arrow F) and WT1 (C, G, K and O; arrow G) as well as for a-SMA (D, H, L and P) showing
arteriolar wall thickening (arrow P). The scale bar in each image measures 50 lm. a-SMA, a-smooth muscle actin.
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The lipid-lowering and insulin-sensitizing effects of
dual PPAR agonists are well-known and have been
reported in rodents and humans. In the present study,
glucose and triglyceride levels were reduced; however, no
change in insulin levels were apparent. PPARa/c agonism
has been reported to restore adiponectin levels and to
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Figure 7. A novel automated image analysis method was used to quantify matrix accumulation and podocyte markers. (A) Relative ratios
between unstained areas and nephrin-stained areas (increased values indicate more damage). (B) Relative nephrin area fractions. (C) Relative
WT1 cell counts/glomerular surface area. All data were divided by the geometric mean for the BTBR lean group and therefore represents fold
change from this value. Data were log-transformed prior to using one-way ANOVA and Dunnett’s post hoc test. *P < 0.05 and **P < 0.01
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Figure 8. Gene expression of podocyte markers are decreased, whereas inflammatory markers are unchanged in BTBRob/ob female mice
compared with lean controls. Levels of mRNA for podocyte markers nephrin (A) and WT1 (B), and inflammatory markers Tnf (C), Ccl2 (D), and
CD68 (E) in renal cortex tissue at 24 weeks of age from lean BTBR (n = 5), BTBRob/ob controls (n = 12), and BTBRob/ob mice with AZD6610
(n = 8) or enalapril (n = 7) treatment. One-way ANOVA followed by Dunnett’s multiple comparisons test were used and data are shown as
means with 95% confidence intervals. ##P < 0.01 and ###P < 0.001 compared with BTBR lean. Ena, enalapril; Nphs1, nephrin; Tnf, tumor
necrosis factor; Ccl2, chemokine (C-C motif) ligand 2, also referred to as monocyte chemoattractant protein 1 (MCP-1).
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lower plasma insulin (Cha et al. 2007), where adiponectin
is known to increase insulin sensitivity (Yamauchi et al.
2001; Kubota et al. 2002). Furthermore, podocyte foot
process effacement and albuminuria have been observed
in adiponectin knockout mice, while adiponectin admin-
istration has been shown to reverse these abnormalities
(Sharma et al. 2008). Adiponectin treatment alone has
been shown to reduce albuminuria and renal fibrosis,
which are thought to result from the anti-inflammatory
and angiotensin-blocking effects of adiponectin (Guo
et al. 2014). Hyperinsulinemia is known to correlate with
albuminuria (Sarafidis et al. 2010), but in the present
study there were no detectable changes in insulin or adi-
ponectin plasma concentrations in response to AZD6610
treatment. The lack of effect of AZD6610 on albuminuria
could be due to a failure to restore adiponectin or lower
insulin levels. Indeed, treatment with PPAR agonists has
been shown to be more efficacious in correcting meta-
bolic dysfunction and development of proteinuria when
given as preventive treatment, rather than as an interven-
tion, in aged animals with severe diabetes (Smith et al.
2000).
To explore the lack of effect of AZD6610 on albumin-
uria, the expression of the podocyte markers nephrin and
WT1 was investigated. A lower count in podocyte cell
number has been reported in the BTBRob/ob mouse
model as early as 8 weeks of age (Hudkins et al. 2010),
and although podocyte cell counting was not performed,
nephrin and WT1 staining were found to be reduced
compared with BTBR lean controls, both at the mRNA
and protein expression levels at 24 weeks age. AZD6610
did not seem to improve any of the podocyte markers
measured semiquantitatively. Podocyte protective effects
and improved renal function have been reported with
PPAR agonism in a nondiabetic model of podocyte injury
(FSGS) (Yang et al. 2006), but in the current study, insuf-
ficient podocyte protection may partly explain the lack of
effect on albumin excretion.
In previous studies with enalapril, there has been a
robust decrease in albuminuria in BTBRob/ob mice (A.
Ericsson, unpubl. obs.) and in the present study, albu-
minuria was decreased by enalapril treatment, although
nephrin mRNA and protein expression appeared to be
unchanged by enalapril. While no effect on matrix expan-
sion was detectable in the present study, a modest effect
has been reported previously in the BTBRob/ob mouse
model (Pichaiwong et al. 2013), and may suggest some
limitation to the benefits of RAS blockade in DN. There
was also a trend for lower glucose concentrations in ena-
lapril-treated mice, without observable differences in daily
food intake (data not shown) or body weight. Although
glucose lowering in response to enalapril has not been
reported in the BTBRob/ob model before, a reduced
incidence in the onset of diabetes has been observed in
clinical trials using ACE inhibitors (Solski and Longyhore
2008), and RAS blockade in a diabetic rat model has been
shown to attenuate islet cell damage and to augment
beta-cell mass (Tikellis et al. 2004).
Inflammation is a recognized component of human
and experimental DN and is typically characterized by
infiltrating macrophages. There is some evidence for
inflammation in the BTBRob/ob mouse model shown
previously by Hudkins et al. (2010), who reported
increased Mac-2-positive monocyte/macrophages in
glomeruli of 22-week-old female mice. Treatment with
enalapril has been shown to reduce the number of
Mac-2-positive cells (Pichaiwong et al. 2013); however,
the use of CP-900691, a PPARa agonist, did not affect
Mac-2-positive cell numbers (Askari et al. 2014). In the
current study, no statistically detectable change in mRNA
expression of the inflammatory markers TNFa (Tnf),
MCP-1(Ccl2), or CD68 was observed in cortical tissue
comparing BTBRob/ob with lean controls or between
nontreated BTBRob/ob and enalapril or AZD6610 treated
mice. The BTBRob/ob mouse model recapitulates more
reliably glomerular changes seen in human DN and there-
fore gene expression analysis performed in isolated glo-
meruli may capture more readily any small inflammatory
changes.
The finding of arteriolar remodeling was limited to the
enalapril-treated group and is similar to the feature of
concentric hypertrophy seen in malignant hypertension.
This is a novel and unexpected finding occurring in the
absence of an elevated blood pressure in this model
(Hudkins et al. 2010). This type of lesion has not been
reported before, but it has been noted consistently in sev-
eral previous unpublished studies (A. Ericsson, unpubl.
obs.). The underlying mechanism for this is unclear, but
since this form of vascular remodeling has not been
reported in association with an ACE inhibitor or enalapril
itself in patients, or in wild-type rodent species, it may
depend on the BTBR background or in deranged leptin
functionality.
Conclusions
Taken together, these results confirm previous findings of
mesangial expansion, progressive albuminuria, and podo-
cyte loss in the BTBRob/ob mouse. However, this model
does not seem to recapitulate all the features of human
DN, including robust GBM thickening, but it does show
hyperfiltration that persists in older animals. Both
PPARa/c agonism by AZD6610 treatment and ACE inhi-
bition by enalapril treatment had no or only a limited
effect on mesangial expansion and albuminuria. The vas-
cular remodeling seen with enalapril treatment may limit
2017 | Vol. 5 | Iss. 5 | e13186
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its potentially beneficial effects in this particular animal
model of DN.
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